Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.54 |
| ▸ | MAG | P20916 | 6/20 | 0.38 |
| ▸ | CD22 | P20273 | 4/20 | 0.38 |
| ▸ | SELL | P14151 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837962 | 0.88 | NANP (0.52) | NANPMAGCD22 | |
| SCHEMBL28161285 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL7066109 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL2742889 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL13125452 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL15976325 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL8489507 | 0.81 | NANP (0.74) | NANPMAGCD22SELLSELP | |
| SCHEMBL14752226 | 0.80 | NANP (0.43) | NANPMAGCD22SELLSELP | |
| SCHEMBL15321632 | 0.80 | NANP (0.61) | NANPMAGCD22 | |
| SCHEMBL14601223 | 0.79 | NANP (0.63) | NANPMAGCD22SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100876-A1 | Method of Treating of Fibroblast Growth Factor 21 (FGF-21) Deficiency | 89BIO, INC. | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100876-A1 | Method of Treating of Fibroblast Growth Factor 21 (FGF-21) Deficiency | FGF2, FGF1, FGFR1 | NANP 260/4885MAG 1560/4885CD22 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.